Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2014

View Archived Issues

Potency of a novel NRTI against drug-resistant retroviruses

Phase III clinical data for DTaP5-IPV-Hib-HepB vaccine in infants

GW Pharmaceuticals provides new physician reports of Epidiolex

Capricor Therapeutics acquires rights to family of natriuretic peptides

DKFZ to evaluate Imaxio's pro-immunogenic technology in HPV vaccine

Johnson & Johnson reports on active third quarter 2014

NanoLogix configuring N-Assay Rapid diagnostic kits for viruses

Idera's IMO-9200 moves into phase I development

Compound derived from traditional Chinese medicine has antipsoriatic activity

Purdue Pharma patents novel Nav1.7 blockers for pain

New BUB1 inhibitors disclosed by Bayer Schering Pharma for cancer

Researchers at Aptose Biosciences patent new agents for cancer

Beta cell-specific insulin gene knockout model reveals pancreatic cell fate in diabetes

Actinobac Biomed receives second NIH grant to support development of Leukothera

Novel Nav1.7 blockers divulged by Genentech and Xenon Pharmaceuticals

Advaxis reports preliminary data from phase I/II trial of ADXS-HPV in anal cancer

ActoGeniX reports data from phase I study of AG-014

FDA approves two idiopathic pulmonary fibrosis drugs ahead of schedule

Hanmi Pharmaceuticals and Kinex Pharmaceuticals report data from phase I Oratecan study

Alexion submits NDA in Japan for asfotase alfa

Retrophin to divest non-core assets to Turing Pharmaceuticals

FDA clears Lyra Parainfluenza Assay for use

FDA issues refusal to file letter in response to Insys' NDA for dronabinol

FDA grants priority review for lenvatinib in thyroid cancer

Nivolumab and ipilimumab combination receives FDA orphan drug designation

Compstatin 40 given U.S. orphan drug status for paroxysmal nocturnal hemoglobinuria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...